Cheryl S Broussard

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. doi request reprint Maternal treatment with opioid analgesics and risk for birth defects
    Cheryl S Broussard
    Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Obstet Gynecol 204:314.e1-11. 2011
  2. doi request reprint Racial/ethnic differences in infant mortality attributable to birth defects by gestational age
    Cheryl S Broussard
    Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 130:e518-27. 2012
  3. doi request reprint Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States
    Suzanne M Gilboa
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Am J Med Genet C Semin Med Genet 157:234-46. 2011
  4. doi request reprint Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007
    Jennifer N Lind
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Pharmacoepidemiol Drug Saf 22:783-93. 2013
  5. doi request reprint Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011
    Stacey L Peters
    Rollins School of Public Health, Emory University, Atlanta, GA, USA
    Pharmacoepidemiol Drug Saf 22:324-8. 2013
  6. pmc Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004
    Alicia E Genisca
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Med Genet A 149:1149-58. 2009
  7. doi request reprint Herbal use before and during pregnancy
    Cheryl S Broussard
    Epidemic Intelligence Service, Office of Workforce and Career Development, Division of Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Obstet Gynecol 202:443.e1-6. 2010

Collaborators

Detail Information

Publications7

  1. doi request reprint Maternal treatment with opioid analgesics and risk for birth defects
    Cheryl S Broussard
    Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Obstet Gynecol 204:314.e1-11. 2011
    ..We examined whether maternal opioid treatment between 1 month before pregnancy and the first trimester was associated with birth defects...
  2. doi request reprint Racial/ethnic differences in infant mortality attributable to birth defects by gestational age
    Cheryl S Broussard
    Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 130:e518-27. 2012
    ..Previous reports have highlighted black-white differences in overall infant mortality and infant mortality attributable to birth defects (IMBD). We evaluated the impact of gestational age on US racial/ethnic differences in IMBD...
  3. doi request reprint Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States
    Suzanne M Gilboa
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Am J Med Genet C Semin Med Genet 157:234-46. 2011
    ..This modeling approach could be extended to other medications to estimate the impact of translating pharmacoepidemiologic data to evidence-based prenatal care practice...
  4. doi request reprint Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007
    Jennifer N Lind
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Pharmacoepidemiol Drug Saf 22:783-93. 2013
    ..To investigate associations between maternal use of common medications and herbals during early pregnancy and risk for hypospadias in male infants...
  5. doi request reprint Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011
    Stacey L Peters
    Rollins School of Public Health, Emory University, Atlanta, GA, USA
    Pharmacoepidemiol Drug Saf 22:324-8. 2013
    ..Medication use during pregnancy is common and increasing. Women are also increasingly getting healthcare information from sources other than their physicians...
  6. pmc Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004
    Alicia E Genisca
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Med Genet A 149:1149-58. 2009
    ..Better understanding of the birth prevalence and phenotype may help guide clinical care as well as contribute to an improved understanding of pathogenesis...
  7. doi request reprint Herbal use before and during pregnancy
    Cheryl S Broussard
    Epidemic Intelligence Service, Office of Workforce and Career Development, Division of Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Obstet Gynecol 202:443.e1-6. 2010
    ..We estimated the prevalence and patterns of herbal use among US women before and during pregnancy...